By the Top Tier Newswire AI Desk · July 23, 2026 at 11:25 AM ET · reviewed against 3 wire stories
ARGENX SE ADR (ARGX) is up +6.52% in the latest session. Our newswire has captured 3 stories on ARGX across 3 sources in the last 36 hours, with AI sentiment reading bullish (avg 68/100).
ARGX stock rose 6.52% to $907.25 on Tuesday, driven by strong second quarter financial results and positive analyst coverage. The biopharmaceutical company reported 60% year-over-year growth in product sales, with its lead drug, VYVGART, expanding to all serotypes of generalized myasthenia gravis. Earnings and revenue exceeded estimates, contributing to a sharp intraday rebound after an early dip.
What Happened
The stock opened with a 3.8% gap up from the previous close, but it quickly faced a test near the $850 level. By mid-morning, the price had recovered to near $907, reflecting the positive reception of the company’s quarterly performance. Argenx reported $1.5 billion in global product net sales for the second quarter of 2026, with 60% year-over-year growth and 17% quarter-over-quarter growth. The company also announced the successful expansion of VYVGART, a key driver of its revenue. Earnings per share of $7.32 beat the estimated $6.24, while total sales of $1.542 billion exceeded the projected $1.442 billion. Analysts at Citigroup and RBC Capital raised their price targets, with Citigroup setting a new target of $1182 and RBC of $945.
What The Data Shows
The stock’s intraday session showed a volatile start, with a low of $845.30 shortly after the market opened. It then climbed steadily to a high of $907.47 at 11:20 AM ET. The volume of 0.1 million shares traded so far is 0.4 times the 3-month average, suggesting moderate but growing investor interest. Argenx has a market cap of $54.3 billion, a P/E ratio of 37.9, and trailing twelve-month revenue growth of 79.4%. The stock is currently trading within its 52-week range of $563.08 to $953.58, with a net margin of 31.4%. The improving sentiment trend, with a 7-day average of 68/100, also supports the recent upward momentum.
What To Watch
With earnings already released, the focus will now shift to coverage breadth and analyst reactions in the coming days. Investors should monitor how the market responds to the updated price targets and any new developments from the company’s pipeline.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.